WALTHAM,
Mass., May 15, 2024 /PRNewswire/ -- Spyre
Therapeutics, Inc. (NASDAQ: SYRE) (the "Company" or "Spyre"), a
development-stage biotechnology company advancing best-in-class
antibody engineering, rational therapeutic combinations, and
precision medicine approaches for the treatment of Inflammatory
Bowel Disease ("IBD"), today announced the appointment of
Sandra Milligan, M.D., J.D.,
President of Aspira Women's Health, to its Board of Directors.
"With a distinguished career spanning leadership roles at large
and small biopharmaceutical companies, Dr. Milligan brings deep
expertise in clinical development and regulatory affairs, including
within IBD, that will be invaluable as we execute on our strategy
to deliver novel therapies that improve both efficacy and
convenience compared to today's standard of care," said
Cameron Turtle, DPhil, Chief
Executive Officer of Spyre. "We are excited to incorporate her
guidance as we progress our novel antibody therapies targeting α4β7
and TL1A into clinical studies in the upcoming months."
Prior to her current role at Aspira, Dr. Milligan served as the
Head of Research and Development of Organon & Co. Previously,
she served in key executive positions, including Senior Vice
President and Head of Global Regulatory Affairs and Clinical Safety
at Merck; Vice President of Product Development Regulatory at
Genentech, Inc.; and important roles across legal and regulatory
affairs at Amgen Inc.
"As a physician, Spyre's commitment to scientific excellence and
patient-centric innovation resonates deeply with me," said Dr.
Milligan. "I am honored to join this accomplished team of leaders
and eager to collaborate in their goal to drive meaningful
advancements in IBD treatment toward improving lives."
Dr. Milligan is being appointed as a successor to Russell Cox, whose Board term ended effective
May 13, 2024. We express our
gratitude for Russell's dedicated service as the Chairman of the
Board. Jeffrey Albers, current
member of the Board, has been appointed Chairman in connection with
Russell's departure.
About Spyre Therapeutics
Spyre Therapeutics is a biotechnology company that aims to
create next-generation inflammatory bowel disease (IBD) products by
combining best-in-class antibody engineering, rational therapeutic
combinations, and precision medicine approaches. Spyre's pipeline
includes extended half-life antibodies targeting α4β7, TL1A, and
IL-23. For more information, visit Spyre's website at
www.spyre.com.
Follow Spyre Therapeutics on social media: @spyretx and
LinkedIn
Forward-Looking Statements
Certain statements
in this press release, other than purely historical information,
may constitute "forward-looking statements" within the meaning of
the federal securities laws, including for purposes of the safe
harbor provisions under the United States Private Securities
Litigation Reform Act of 1995, concerning Spyre and other matters.
These forward-looking statements include, but are not limited to,
express or implied statements relating to Spyre's management team's
expectations, hopes, beliefs, intentions or strategies regarding
the future including, without limitation, Spyre's ability to
achieve the expected benefits or opportunities with respect to its
pipeline of product candidates such as potential improved dosing
regimens over approved product candidates, Spyre's preclinical and
future clinical development activities, and the potential
therapeutic benefits and economic value of Spyre's product
candidates. In addition, any statements that refer to projections,
forecasts or other characterizations of future events or
circumstances, including any underlying assumptions, are
forward-looking statements. The words "opportunity," "potential,"
"milestones," "pipeline," "can," "goal," "aim," "strategy,"
"target," "seek," "anticipate," "achieve," "believe,"
"contemplate," "continue," "could," "estimate," "expect,"
"intends," "may," "might," "plan," "possible," "predict,"
"project," "should," "will," "would" and similar expressions
(including the negatives of these terms or variations of them) may
identify forward-looking statements, but the absence of these words
does not mean that a statement is not forward-looking. These
forward-looking statements are based on current expectations and
beliefs concerning future developments and their potential effects.
There can be no assurance that future developments affecting Spyre
will be those that have been anticipated. These forward-looking
statements involve a number of risks, uncertainties (some of which
are beyond Spyre's control) or other assumptions that may cause
actual results or performance to be materially different from those
expressed or implied by these forward-looking statements. These
risks and uncertainties include, but are not limited those
uncertainties and factors described under the heading "Risk
Factors" and "Note about Forward-Looking Statements" in Spyre's
most recent Quarterly Report on Form 10-Q filed with the SEC, as
well as discussions of potential risks, uncertainties, and other
important factors included in other filings by Spyre from time to
time. Should one or more of these risks or uncertainties
materialize, or should any of Spyre's assumptions prove incorrect,
actual results may vary in material respects from those projected
in these forward-looking statements. Nothing in this press release
should be regarded as a representation by any person that the
forward-looking statements set forth therein will be achieved or
that any of the contemplated results of such forward-looking
statements will be achieved. You should not place undue reliance on
forward-looking statements in this press release, which speak only
as of the date they are made and are qualified in their entirety by
reference to the cautionary statements herein. Spyre does not
undertake or accept any duty to make any updates or revisions to
any forward-looking statements. This press release does not purport
to summarize all of the conditions, risks and other attributes of
an investment in Spyre.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/spyre-therapeutics-appoints-accomplished-biopharma-leader-dr-sandra-milligan-to-its-board-of-directors-302144858.html
SOURCE Spyre Therapeutics, Inc.